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Postherpetic neuralgia (PHN) is a complication of herpes zoster that contributes to significant 
suffering for many patients.  Analgesics, anticonvulsants, antidepressants, topical formulations 
and some interventional treatments have all been utilized in treating the neuropathic pain 
associated with PHN.  Due to the current opioid epidemic, it is more important than ever for 
providers to find alternative methods of pain control for patients experiencing chronic pain.  
Medications in a variety of classes have shown varying levels of efficacy in providing relief for 
PHN patients, and providers should be aware of the evidence supporting the prescription of these 
treatments.  Evidence supporting the use of gabapentin, pregabalin, amitriptyline, topical 
capsaicin, botulinum toxin injection, vitamin B12 supplementation, and interventional treatments 
has been reviewed to determine efficacy and assist providers in determining best practice when 
prescribing these medications.  Safety considerations related to the previously mentioned 
medications have also been reviewed as available.  Recommendations for use considering the 
quality of available evidence have been provided. 
 Keywords: postherpetic neuralgia, neuropathic pain, anticonvulsants, antidepressants, 
topical formulations, interventional therapies, emerging treatments 
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Non-Narcotic Treatment for Postherpetic Neuralgia 
 Herpes zoster (shingles) is an infectious disease that results from reactivation of the 
varicella zoster virus (chickenpox) that remains present in the dorsal root ganglion after infection 
(Shrestha & Chen, 2018).  The reactivated virus travels along a sensory dermatome, resulting in 
a maculopapular rash with fluid filled vesicles that lasts for about ten days (Saguil et al., 2017).  
There are about one million new occurrences of herpes zoster every year in the United States, 
and it is estimated that about 3 in 10 adults will develop herpes zoster in their lifetime (Saguil et 
al., 2017).  Pain, itching and burning are often experienced along the path of the dermatome prior 
to the rash eruption, with some patients experiencing neuropathic pain long after the rash has 
resolved (Shrestha & Chen, 2018).  Long term neuropathic pain from herpes zoster, better known 
as postherpetic neuralgia (PHN), is the most common complication of shingles with higher 
incidence occurring in patients over age 50 (Saguil et al., 2017).  In this paper, a case report 
about a 70 year old woman who developed shingles will be reviewed.  Due to the diagnosis of 
this patient, as well as her age, she is at high risk of developing PHN, and long term treatment 
may need to be considered for neuropathic pain relief. 
 Current treatments for PHN are wide ranging, include analgesics, anticonvulsants, 
antidepressants, topical formulations, interventional treatments and combination treatments, with 
new treatments in development as well (Shrestha & Chen, 2018).  As with all treatments, there 
are risks and benefits to consider when selecting the right plan for any given patient.  While 
opioid analgesics may be effective in providing pain relief, the number of negative side effects 
and long term dependence issues should make them a last resort when considering the need for 
chronic pain control.  With the availability of so many other options, it is up to providers to be up 
to date on the latest evidence that supports the use of these treatments to treat PHN without 
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having to resort to the use of opioid analgesics.  The purpose of this report is to review currently 
recommended or developing treatments for PHN and determine the quality of evidence 
supporting their use. 
Case Report 
History 
Patient is a 70 year old Caucasian female that presented complaining of back pain that 
began two days ago.  She reports the pain is located in her lower back, on the right side.  She has 
been experiencing the pain off and on over the past two days, but it has been more present than 
not.  She describes the pain as a burning, itching sensation.  It is worse when there is pressure on 
it, like when her clothes rub against it or she lays down on that side.  She has tried taking over 
the counter Tylenol and applying ice to the area which have helped a bit, but the pain continues 
to return after treatment.  She reports that the pain is worse in the evening after she has been 
moving around throughout the day.  She describes the severity of the pain as being a six out of 
ten on a numeric rating scale of 0-10 for pain. 
Past medical history includes hypertension (for which she takes Lisinopril 20 mg PO 
daily) and rheumatoid arthritis (Prednisone 5 mg PO PRN).  Past surgical history includes a 
hysterectomy two years ago, as well as an appendectomy at that time.  Patient has no known 
allergies, and reports she is up to date on all immunizations except for the shingles vaccine.  
Patient’s family history includes heart disease in her mother, she is unaware of any health 
conditions her father may have had.  Patient is a retired secretary that lives at home with her 
husband.  She has two children that live in town and a couple of grandsons.  She spends her time 
gardening and working in her yard when the weather is nice, and sewing during the winter 
months.  Patient denies any smoking history or tobacco use in any form.  She reports drinking 
 6 
the occasional glass of wine with dinner, about 2-3 drinks/month.  Patient denies the use of any 
illegal substances or inappropriate drug use. 
Physical Examination 
 The patient’s blood pressure upon exam was 154/90, pulse was 78 bpm, temperature was 
99.1 orally, and oxygen saturation was 96% on room air.  Patient reported she was in pain, and 
rated her pain a six out of ten.  The patient was in no apparent distress, a systolic grade 2 murmur 
was noted upon cardiac auscultation and lung sounds were clear to anterior and posterior 
auscultation.  Examination of the patient’s back revealed a one inch by five inch cluster of 
reddened skin with raised, yellow, fluid filled vesicles along the right L3 dermatome.  The rash 
began midline to the lower spine and extended along the right side of the patient’s back towards 
the hip, it did not extend across midline or towards the left at all. 
Diagnosis, Treatment and Follow Up 
 The diagnosis in this case was herpes zoster along the right L3 dermatome.  The 
symptoms had been present for approximately 48 hours without any complications, making this 
patient a good candidate for antiviral treatment.  The recommended treatment in this case was 
oral Valacyclovir 1000 mg three times daily for one week.  The goals of this therapy are to 
decrease the length of illness and severity of symptoms associated with herpes zoster (Albrecht, 
2018).  Antiviral therapy can prevent the development of new herpetic lesions as well as improve 
the rate of healing for current lesions (Albrecht, 2018).  Transmission of the herpes zoster virus 
is possible during infection, and antiviral therapy can help decrease viral shedding to lower the 
risk of spreading the disease (Albrecht, 2018).  In addition to the above goals, completing this 
treatment is meant to prevent the development of postherpetic neuralgia in patients with herpes 
zoster (Albrecht, 2018). 
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For acute pain and discomfort associated with an uncomplicated herpes zoster infection, 
the treatment plan should also include NSAIDS or Tylenol while the patient recovers with the 
disease (Albrecht, 2018).  In some instances, like with severe or sleep disturbing pain, opioid 
pain relief has been considered useful for a short amount of time (Albrecht, 2018).  Close patient 
monitoring is recommended while patients are treated and as clinical symptoms resolve.  It is 
recommended that this patient return to clinic at the completion of antiviral therapy, about one 
week later, to assess for healing and pain control (Albrecht, 2018).  The goal is to be able to 
discontinue analgesic treatment of any acute pain associated with shingles.  It is also important to 
provide patient education on the possible long term complication of PHN to this patient due to 
her age. 
Literature Review 
 To begin the literature review on this topic, the PubMed database was first searched for 
relevant research due to the inclusion of biomedical and health literature.  The PubMed search 
was performed using the medical subject headings (MeSH) terms: (a) “postherpetic neuralgia”; 
and (b) “treatment.”  The medical subject headings were combined with the Boolean connector 
“AND” to make sure all topics were included in relevant articles.  Additional limits on the search 
included articles written within the last 5 years, articles written in English, studies limited to 
human subjects, and systematic reviews or meta-analysis articles only in order to obtain the most 
current and relevant articles of the highest quality.  The search resulted in 33 articles that met the 
established criteria.  After reviewing the literature, nine articles were found to contain relevant 
information for non-opioid treatment of PHN. 
 Next, the Cochrane Database of Systematic Reviews was searched to find relevant 
articles.  The previous MeSH terms used in the PubMed search (“postherpetic neuralgia” and 
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“treatment”) were also utilized with the Boolean connector “AND” in an advanced search of the 
Cochrane library.  A limit of articles written after 2015 was also placed on the search.  The 
results of this literature search yielded fifteen articles.  Many of these reviews had been located 
in the PubMed database search, the results of this search only identified one additional article to 
add to the literature review. 
 The PubMed and Cochrane database searches resulted in a total of ten relevant articles 
for the literature review.  Articles with at least moderate-quality evidence were selected for this 
review if the researchers in the studies presented this information.  Bias within the articles was 
also taken in to account to prevent inclusion of too many articles with a high risk of bias.  The 
selected articles include four meta-analyses (Song et al, 2018; Wang et al., 2018; Wang et al., 
2017; Zhang et al, 2018), five systematic reviews (Derry et al, 2019; Derry et al., 2017; Lin et 
al., 2019; Moore et al., 2015; Wiffen et al., 2017), and one systematic review with meta-analysis 
(Shackleton et al., 2016).  These ten articles review current and emerging non-opioid treatments 
for PHN. 
Gabapentin 
 Two studies directly evaluated the use of gabapentin, an anticonvulsant, for the treatment 
of PHN.  In a meta-analysis of gabapentin efficacy, eleven randomized control trials were 
evaluated comparing the use of gabapentin with placebo in reducing pain intensity (Zhang et al., 
2018).  All clinical trials were randomized and double-blinded, with parallel and placebo design, 
providing high quality evidence to be used for the meta-analysis.  All eleven studies showed 
positive results for gabapentin over placebo in reducing patient pain intensity by at least 50% 
[RR=-1.79, 95% CI= 1.43, 2.25, P<0.00001] (Zhang et al., 2018).  The analysis also revealed 
that gabapentin led to improved sleep rating scores for patients suffering from PHN (Zhang et 
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al., 2018).  All studies recognized the downfall of adverse events related to the use of gabapentin, 
which included peripheral edema, dizziness and somnolence reported by subjects (Zhang et al., 
2018).  Despite these adverse events, subjects found that the significant pain relief outweighed 
the adverse effects of gabapentin usage during the study.  Three different formulations of 
gabapentin were included: an immediate release form, an extended release form, and an extended 
release form including enacarbil, a prodrug to gabapentin.  Of the three formulations, the 
gabapentin with enacarbil provided the best pain relief and improved sleep scores to subjects, 
with no notable difference in adverse effects in comparison to the other formulations (Zhang et 
al., 2018). Researchers believe that further studies need be done on the long-term safety and 
efficacy of gabapentin usage for PHN relief (Zhang et al, 2018).  Notable limitations to this 
analysis include a lack of diversity in study subjects and a lack of long-term usage results (Zhang 
et al., 2018). 
 A Cochrane systematic review on the use of gabapentin for treatment of neuropathic pain 
yielded similar results regarding the relief of pain in patients with PHN (Wiffen et al., 2017).  
The review included eight studies focused on subjects with PHN, with an average of 32% of 
subjects in these studies reporting at least a 50% reduction of pain severity score [RR=1.69, 95% 
CI= 1.43-2.0, P= 0.020] (Wiffen et al., 2017).  This review also included evidence of at least 
moderate quality, yielding higher reliability in study findings.  The Cochrane review endorsed 
higher occurrences of adverse effects with gabapentin including gait disturbance in addition to 
the previously mentioned adverse effects, but did note that no serious adverse events occurred 
with gabapentin use over placebo (Wiffen et al., 2017).  An important limitation noted in this 
study was the inclusion of some smaller study sizes that may introduce higher levels of bias into 
the review (Wiffen et al., 2017). 
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Pregabalin 
 In the evaluation of pregabalin as treatment for postherpetic pain, the other highly utilized 
anticonvulsant for this purpose, a meta-analysis and systematic review were used.  The meta-
analysis of pregabalin use directly analyzed it’s efficacy in providing pain control for patients 
with PHN.  This analysis reviewed seven studies, and that found more subjects reported at least 
50% pain relief with pregabalin than with a placebo treatment [RR=1.15, 95% CI, 1.03, 1.29, 
P=0.010] (Wang et al., 2017).  Patients in the analyzed studies reported less sleep interference 
when taking pregabalin leading to increase sleep quality for PHN patients (Wang et al., 2017).  
One negative of pregabalin noted in the study was cost, but current evaluation of the market 
recognizes a generic is now available which may make this a more realistic option for some 
patients.  While two studies in the analysis did not describe their randomization process, the five 
remaining studies were performed with low risk of bias, improving the reliability of the results 
compared in this analysis (Wang et al., 2017).  Adverse effects of pregabalin were not evaluated 
in this study, which may be a future area to consider in evaluating the safety of this medication 
for treating PHN. 
 Pregabalin use for neuropathic pain also received a Cochrane systematic review, with 
eight studies focused on its use specifically for PHN (Derry et al., 2019).  The eight studies were 
all randomized control trials comparing pregabalin with placebo, all with parallel designs.  While 
some studies in the entire systematic review were recognized to have a high risk of bias due to 
sample size, the studies included for the use of pregabalin to treat PHN had larger sized studies, 
eliminating a higher risk for bias.  This review did have studies that evaluated the different 
efficacy between 300 mg and 600 mg doses, and found that for patients reporting at least a 50% 
reduction in their pain rating, the 600 mg dose was slightly more effective than to 300 mg dose 
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[RB=2.7, 95% CI 2.0-3.5 for 600 mg, vs. RB=2.5, 95% CI 1.9-3.4 for 300 mg] (Derry et al., 
2019).  The evidence in this review received a moderate quality rating, which indicates the 
improvement in pain relief is most likely due to the pregabalin, at whichever dose the patient is 
receiving.  This review did find that the adverse effects of dizziness and sleepiness were more 
common in patients receiving pregabalin instead of placebo, but did not find any significant 
difference in severe adverse events between treatment and placebo groups (Derry et al., 2019). 
Amitriptyline 
 There was one Cochrane systematic review that evaluated the efficacy of amitriptyline 
for neuropathic pain, the most popular antidepressant utilized in treating PHN.  This review 
included five studies that compared efficacy of amitriptyline with various other psychoactive 
drugs (fluphenazine, lorazepam, desipramine, maprotiline, nortriptyline and fluoxetine) in 
addition to placebo (Moore et al., 2015).  Some studies included a cross-over design, but all were 
actively controlled.  Study comparisons between amitriptyline and the other drugs varied in 
efficacy, and there was no convincing evidence that supported the efficacy of amitriptyline as 
being superior to any other treatment (Moore et al., 2015).  Study sizes within this review were 
notably small, resulting in increased bias which further limited the low quality evidence 
supporting the use of amitriptyline.  One notable recommendation about this treatment is that 
many guidelines still recognize amitriptyline as the first line of treatment for neuropathic pain, 
often at lower doses than recommended for use as an antidepressant (Moore et al., 2015).  While 
this does contradict the lack of quality evidence provided by this review, the researchers did 
acknowledge that providers should continue to use this as a treatment option due to the length of 
time patients have reported good outcomes with use, and the fact that there was also no evidence 
supporting that amitriptyline had no effect on neuropathic pain (Moore et al., 2015). 
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Topical Capsaicin 
 Topical application of high concentration capsaicin in treating neuropathic pain also 
received a Cochrane systematic review, with four studies in the review focused on its use 
specifically for PHN.  One difficulty noted in this review was for studies to truly be blinded, due 
to side effects like redness and burning produced at the application site by any product 
containing capsaicin, which were also the most notable adverse events reported in the study for 
both treatment groups (Derry et al., 2017).  A subject receiving a true placebo would not 
experience these side effects, therefore the participants were given a very low dose capsaicin in 
some trials to compare with a high concentration dose to allow for more reliability in results.  
The results did show that more participants receiving the high concentration capsaicin did report 
at least a 50% reduction in pain severity when compared to the low dose capsaicin or 
placebo[RR=1.44, 95% CI 1.12, 1.86, P= 0.005] (Derry et al., 2017).  One downfall of the 
findings in this review was the low percentage of participants that did report pain reduction, 
which signifies that while it may be highly effective, it may also only be effective for a small 
amount (Derry et al., 2017).  While the review did judge the evidence to be of moderate quality, 
due to some small sample sizes and lack of true blinding in some studies, the evidence was 
downgraded by the reviewers to low quality despite the positive results reported by patients 
(Derry et al., 2017).   
Botulinum Toxin 
 The article supporting the use of botulinum toxin in treating PHN was a systematic 
review with meta-analysis that looked at efficacy for PHN, but also trigeminal neuralgia.  These 
two types of neuropathic pain were not differentiated within the review or analysis.  Six studies 
were reviewed, with only one study found to have a high risk of bias due to having an unclear 
 13 
description of their randomization process (Shackleton et al., 2016).  All studies found that the 
use of botulinum toxin resulted in more pain reduction for participants.  Three of the studies 
measured pain reduction of at least 50% in participants receiving the botulinum toxin 
[RR=2.892, 95% CI 1.726, 4.848, P<0.001], which was 2.9 times more likely to occur with 
treatment than with placebo (Shackleton et al., 2016).  Since the analysis contained a smaller 
amount of articles, reviewers were only able to recommend botulinum toxin treatment be viewed 
as moderate evidence for PHN.  One positive point mentioned in this review was the lack of 
systemic side effects or any adverse events reported by participants, with the only notable side 
effect mentioned being injection site pain (Shackleton et al., 2016).  However, since there were a 
limited amount of studies to review, further studies would have to be performed to truly evaluate 
for all possible side effects. 
Vitamin B12 
 One meta-analysis evaluated the efficacy of Vitamin B12 supplementations in reducing 
pain associated with PHN.  This analysis included four randomized control trials with rather high 
reliability due to lack of bias (Wang et al., 2018).  The reduction of pain measurement in this 
analysis was different than the other articles in this review, with decrease in score using the 
numerical rating scale being evaluated.  Overall, results for patients receiving the B12 
supplementation were positive, show significantly decreased score after supplementation [MD= -
4.01, 95% CI -4.7, -3.33, P<0.01] (Wang et al., 2018).  With these promising results and low 
risk of bias, reviewers deemed Vitamin B12 supplementation to be moderate quality evidence for 
PHN treatment (Wang et al., 2018).  Of note, there were smaller sample sizes and less studies in 
this analysis than others, which may limit how significant of an effect this may result in for all 
patients.  Also, the study noted that more participants were recruited during the acute herpetic 
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neuralgia stage than the postherpetic stages, which may mean that results might not apply as well 
to all patients with postherpetic neuralgia (Wang et al., 2018). 
Interventional Treatments 
 One systematic review looked at a number of interventional treatments to treat PHN, 
which may be useful after patients have failed to receive relief with typical oral medications or 
topical treatments.  The interventional treatments reviewed included various nerve injections, 
different types of nerve stimulation, spinal cord stimulation, and dorsal root ganglion destruction 
(Lin et al., 2019).  Due to a variety of different treatments with different measures being 
evaluated in this review, the reviewers did not make any specific comparisons between the 
treatments.  It was noted that a lack of studies for all interventions and high or unclear risk of 
bias in most studies may severely limit the applicability of this review (Lin et al., 2019).  The 
reviewers recommended that procedure invasiveness, cost of treatment and patient safety all be 
considered when determining an interventional treatment, as no single treatment was found to be 
more effective than another (Lin et al., 2019).  Nerve injections with botulinum toxin or 
triamcinolone, stellate ganglion nerve block, transcutaneous electrical nerve stimulation, or 
peripheral nerve stimulation should be considered as the first interventional treatments to utilize 
for PHN (Lin et al., 2019).  Paravertebral block or pulsed radiofrequency would be the next line 
of treatments to attempt, and spinal cord stimulation may be used for persistent pain.  Two 
interventional treatments, dorsal root ganglion destruction and intrathecal methylprednisolone 
injections, had the highest amount of adverse events and were only recommended as a last resort 
treatment to be performed by an expert in these procedures (Lin et al., 2019).  The reviewers did 
grade their evidence to be of moderate quality with value to be considered in treating PHN, but 
should not be used as standard treatments (Lin et al., 2019). 
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Treatment Comparisons 
 Limited studies were available that compared all of the previously mentioned treatments 
for PHN with each other, but one meta-analysis did attempt to compare a number of different 
treatments.  Reviewers conducted an analysis comparing topical therapies, antiepileptics, 
analgesics, antipsychotics, antidepressants, anti-dementia drugs, antivirals and magnesium 
sulfate, and provided rankings on how each treatment performed on providing pain relief for 
PHN (Song et al., 2018).  Of the treatments analyzed that were not analgesics, magnesium 
sulfate received the highest rank for PHN treatment (Song et al., 2018).  It is noted that only one 
study in the meta-analysis included this treatment for comparison, and the sample size in the 
study was quite small, making this result considerably biased and significantly limited (Song et 
al., 2018).  The next three highest ranking treatments, in order of efficacy, were antidepressants 
(amitriptyline, nortriptyline, TCAs), antiepileptics (gabapentin, pregabalin, divalproex sodium, 
carisbamate) and topical therapies (capsaicin, lidocaine), all with sufficient evidence to support 
their practical use in treating PHN (Song et al., 2018).  This analysis did recognize that not all 
treatments within a certain class were equal in their ability to treat PHN, i.e. gabapentin 
outperformed carisbamate in the antiepileptic class (Song et al., 2018).  Of the topical therapies 
mentioned in this analysis, both capsaicin and lidocaine were noted to perform well, but limited 
recent evidence supporting the use of lidocaine was found in the entire body literature.  Further 
review of lidocaine efficacy within the topical treatment class would be recommended to 
determine its use as a treatment for PHN.  Anti-dementia drugs and antipsychotics were ranked 
next, and antivirals (which are typically used as prevention) actually ranked below placebo in 
pain reduction for PHN (Song et al., 2018).  The last three treatments mentioned do not have a 
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lot of evidence in current literature, which does not support their use at this time due to the 
number of other treatments available with proven efficacy. 
Learning Points 
• Management of PHN can be achieved for many patients without the long term use of 
opioid analgesics 
• Gabapentin, pregabalin and amitriptyline can provide significant reduction for many 
patients with PHN, and should be considered as first line treatment options 
• Topical use of capsaicin (and possibly lidocaine) can also be useful in treating PHN, and 
are considerable options for second line treatment 
• Botulinum toxin injections and other interventional treatments may be of value in treating 
refractory pain due to PHN 
• Vitamin B12 supplementation in combination with other treatments may provide 
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